Skip to main content

Advertisement

SpringerLink
Log in

Targeted therapies

Treating advanced kidney cancer—miles to go before we sleep

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

A randomized phase III trial comparing pazopanib with sunitinib in patients with advanced clear cell renal cell carcinoma showed that although progression-free survival and overall survival were similar, pazopanib was better tolerated. Recent advances in genomics and metabolomics have provided novel insights that could be leveraged to improve therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Motzer, R. J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369, 722–731 (2013).

    Article  CAS  Google Scholar 

  2. Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860–867 (2013).

    Article  CAS  Google Scholar 

  3. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360–363 (2010).

    Article  CAS  Google Scholar 

  4. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011).

    Article  CAS  Google Scholar 

  5. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).

  6. Hakimi, A. A. et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 19, 3259–3267 (2013).

    Article  CAS  Google Scholar 

  7. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277–285 (2010).

    Article  CAS  Google Scholar 

  8. Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380–384 (2011).

    Article  Google Scholar 

  9. Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385–388 (2011).

    Article  Google Scholar 

  10. Linehan, W. M. et al. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 61, 329–343 (2010).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The authors thank Christopher Rickets for critical reading of the manuscript and acknowledge the outstanding editorial and graphics support by Georgia Shaw.

Author information

Authors and Affiliations

  1. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC Room 1W-5940, Bethesda, 20892, MD, USA

    W. Marston Linehan & Ramaprasad Srinivasan

Authors
  1. W. Marston Linehan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ramaprasad Srinivasan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Marston Linehan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Linehan, W., Srinivasan, R. Treating advanced kidney cancer—miles to go before we sleep. Nat Rev Clin Oncol 10, 614–615 (2013). https://doi.org/10.1038/nrclinonc.2013.183

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.183

  • Springer Nature Limited

This article is cited by

Search

Navigation